MARKET

GTBP

GTBP

Gt Biopharma Inc
NASDAQ
0.4364
-0.0406
-8.51%
After Hours: 0.4200 -0.0164 -3.76% 19:56 06/05 EDT
OPEN
0.4700
PREV CLOSE
0.4770
HIGH
0.4700
LOW
0.4257
VOLUME
1.33M
TURNOVER
--
52 WEEK HIGH
3.850
52 WEEK LOW
0.2610
MARKET CAP
15.74M
P/E (TTM)
-0.0357
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 6d ago
GT Biopharma expects multiple AI-driven development candidates to enter pre-IND stage in 2027
PUBT · 6d ago
GT BIOPHARMA - TO EXPAND PIPELINE TARGETS BEYOND ONCOLOGY IN 2027
Reuters · 6d ago
GT BIOPHARMA PROVIDES UPDATE ON PIPELINE DISCOVERY ACTIVITIES FROM NEWLY IMPLEMENTED AI-BASED TECHNOLOGICAL INITIATIVES
Reuters · 6d ago
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout
Benzinga · 6d ago
Weekly Report: what happened at GTBP last week (0525-0529)?
Weekly Report · 6d ago
The $13 Million Company Teaching the Immune System to Hunt Cancer
Barchart · 05/29 08:00
Weekly Report: what happened at GTBP last week (0518-0522)?
Weekly Report · 05/25 09:11
More
About GTBP
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Webull offers GT Biopharma Inc stock information, including NASDAQ: GTBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GTBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GTBP stock methods without spending real money on the virtual paper trading platform.